Abbott's SonicForce IVL Trial Shows Strong 30-Day Results, Supporting Coronary Device Pipeline

What happened

Abbott announced positive 30-day outcomes from the TECTONIC IDE study for its investigational SonicForce Coronary Intravascular Lithotripsy System, designed to treat calcified coronary lesions. The press release highlights high procedural success and a differentiated design with longer treatment lengths, more pulses, and enhanced deliverability. This development reinforces Abbott's coronary devices portfolio and complements its existing imaging and stent technologies. The master report emphasizes Abbott's product-cycle execution in Medical Devices as a key growth driver, with the segment growing 8% ex-FX in the first half of 2026. While the news is positive, SonicForce is not yet approved, and the trial's longer-term outcomes remain to be validated, so the impact on near-term financials is limited.

Implication

If SonicForce gains FDA approval and achieves commercial traction, it could further strengthen Abbott's high-growth Medical Devices segment and support the bull case of sustained 9%+ growth. However, the exact timing and competitive landscape (e.g., versus Shockwave Medical's IVL system) are uncertain. Investors should monitor approval milestones and adoption, but for now, the thesis remains intact: wait for a better entry near $98 or until clearer catalysts emerge on device growth, Libre remediation, and Exact Sciences margin contribution.

Thesis delta

The thesis is not fundamentally altered by this news. SonicForce is a promising addition to Abbott's device portfolio and aligns with the existing product-cycle execution narrative, but it is still investigational and unlikely to contribute revenue in the near term. The master report's WAIT rating and valuation concerns remain unchanged, as the stock trades at 34.5x earnings with limited margin of safety.